Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APP | P05067 | 3/20 | 0.50 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | GRM5 | P41594 | 1/20 | 0.32 |
| ▸ | BRD4 | O60885 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19787602 | 1.00 | APP (0.50) | APPPTGS2SMN1; SMN2GRM5BRD4 | |
| SCHEMBL19787586 | 1.00 | APP (0.50) | APPPTGS2SMN1; SMN2GRM5BRD4 | |
| SCHEMBL21093628 | 0.71 | CACNA1B (0.40) | — | |
| SCHEMBL19787627 | 0.71 | SMN1; SMN2 (0.53) | APPSMN1; SMN2KDM4E | |
| SCHEMBL30639135 | 0.71 | SMN1; SMN2 (0.53) | APPSMN1; SMN2KDM4E | |
| SCHEMBL21273696 | 0.69 | APP (0.50) | APP | |
| SCHEMBL21883180 | 0.65 | PTGS2 (0.38) | PTGS2HRH3 | |
| SCHEMBL21001348 | 0.62 | SMN1; SMN2 (0.50) | APPSMN1; SMN2KDM4E | |
| SCHEMBL29801652 | 0.61 | APP (0.54) | APP | |
| SCHEMBL19787521 | 0.61 | APP (0.54) | APP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3481829-B1 | FUSED PYRIMIDINE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2021-04-07 | — | — | EP | disclosed |
| EP-3484884-B1 | FUSED PYRIMIDINE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2021-01-27 | — | — | EP | disclosed |
| US-10730881-B2 | Fused pyrimidine derivatives | HOFFMANN-LA ROCHE, INC. (US) | 2020-08-04 | — | — | US | disclosed |
| US-10669276-B2 | Fused pyrimidine derivatives | HOFFMANN-LA ROCHE INC. (US) | 2020-06-02 | — | — | US | disclosed |
| US-20190256517-A1 | FUSED PYRIMIDINE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2019-08-22 | — | — | US | disclosed |
| US-20190177329-A1 | FUSED PYRIMIDINE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2019-06-13 | — | — | US | disclosed |
| WO-2018011164-A1 | FUSED PYRIMIDINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2018-01-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10730881-B2 | Fused pyrimidine derivatives | APP, UPF1, PSEN1 | APP 1/4885PTGS2 803/4885SMN1; SMN2 1523/4885 |
| US-20190256517-A1 | FUSED PYRIMIDINE DERIVATIVES | C9, APP, HPGDS | APP 2/4885PTGS2 790/4885SMN1; SMN2 2364/4885 |
| US-10669276-B2 | Fused pyrimidine derivatives | APP, APOB, C9 | APP 1/4885PTGS2 948/4885SMN1; SMN2 2483/4885 |
| US-20190177329-A1 | FUSED PYRIMIDINE DERIVATIVES | APP, UPF1, PSEN1 | APP 1/4885PTGS2 803/4885SMN1; SMN2 1523/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.